What’s the current market cap for Precigen stock?

Precigen (PGEN) has a market cap of $2bn as of July 04, 2026.

What is the P/E ratio for Precigen stock?

The price to earnings (P/E) ratio for Precigen (PGEN) stock is 0 as of July 04, 2026.

Does Precigen stock pay dividends?

No, Precigen (PGEN) stock does not pay dividends to its shareholders as of July 04, 2026.

When is the next Precigen dividend payment date?

Precigen (PGEN) stock does not pay dividends to its shareholders.

What is the beta indicator for Precigen?

Precigen (PGEN) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Precigen stock | $PGEN Share Price

About Precigen

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Ticker

$PGEN

Sector

Health

Primary listing

NASDAQ

Employees

160

Headquarters

Germantown, United States

Website

precigen.com

Precigen Metrics

BasicAdvanced

$2bn

-

-$1.17

1.07

-

What the Analysts think about Precigen

Analyst ratings (Buy, Hold, Sell) for Precigen stock.

Bulls say / Bears say

The US launch of PAPZIMEOS drove $3.4 million in net product revenue in Q4 2025 and ramped to $21.6 million in product sales in Q1 2026, resulting in total revenues of $23.3 million. (Stockwatch) (TradingView)

Precigen ended 2025 with $100.4 million in cash and investments, which management expects will fund operations through cash-flow break-even by the end of 2026. (MarketBeat)

Precigen is advancing PRGN-2009 into a Phase II trial with early combination data showing a 30% objective response rate in HPV-associated cancers, and is planning pediatric Papzimeos trials by end-2026 with redosing studies in 2028, offering multiple near-term catalysts. (Yahoo Finance)

Precigen reported a net loss of $429.6 million for the full year 2025, compared to revenues of just $9.7 million, highlighting a substantial imbalance between spend and sales. (TradingView)

As of March 31, 2026, cash, cash equivalents, and investments declined to $56.7 million against $93.5 million of long-term debt, raising concerns about funding runway without additional financing. (TradingView) (SEC 10-Q)

Outside of PAPZIMEOS, all other pipeline candidates remain in early Phase I/II stages, exposing the company to high clinical risk before any meaningful diversification of revenue. (Stockanalysis)

Data summarised monthly by Lightyear AI. Last updated on 17 Jun 2026.

Precigen Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Precigen Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Precigen News

AllArticlesVideos

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Accesswire·3 weeks ago

Precigen Q1 Earnings Call Highlights

MarketBeat·2 months ago

Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million

Accesswire·3 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.